Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
Clinical trial NCT05113251 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05113251
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-25
- Primary completion
- 2025-03-12
- Enrollment
- 927
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.